Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts

Oncology Reports

Volumn 29, Issue 1, 2013, Pages 260-268

  Chen, Shan ^a   Liu, Xiaoxia ^a   Gong, Wenfei ^a   Yang, Huan ^a   Luo, Daofei ^a   Zuo, Xialin ^a   Li, Wenshi ^a   Wu, Ping ^a   Liu, Li ^a   Xu, Qian ^a   Ji, Aimin ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy agent; Epidermal growth factor receptor; SiRNA; Vascular endothelial growth factor receptor 2

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; POLYETHYLENEIMINE; SMALL INTERFERING RNA; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENTIATION; EGFR GENE; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR XENOGRAFT; VALIDATION STUDY; VEGFR2 GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CISPLATIN; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84872855358     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2097     Document Type: Article

References (40)

1. Gimbrone MA, Leapman Jr. SB, Cotran RS, et al: Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 136: 261-276, 1972.
2. Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410, 2003.
3. Folkman J: Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273-286, 2007.
4. Brown LF, Detmar M, Claffey K, et al: Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 79: 233-269, 1997.
5. Herbert SP and Stainier DY: Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat Rev Mol Cell Biol 1: 551-564, 2011.
6. Hynes NE and Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354, 2005.
7. Wells A: EGF receptor. Int J Biochem Cell Biol 31: 637-643, 1999.
8. Ciardiello F and Tortora G: Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 39: 1348-1354, 2003.
9. Morelli MP, Cascone T, Troiani T, et al: Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. J Cell Physiol 208: 344-353, 2006.
10. Nicholson RI, Gee JM and Harper ME: EGFR and cancer prognosis. Eur J Cancer 37 (Suppl 4): S9-S15, 2001.
11. Kerbel RS: Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312: 1171-1175, 2006.
12. Dancey JE and Freidlin B: Targeting epidermal growth factor receptor - are we missing the mark? Lancet 362: 62-64, 2003.
13. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427-434, 2003.
14. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
15. Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62, 2005.
16. Wang Y, Li Z, Han Y, et al: Nanoparticle-based delivery system for application of siRNA in vivo. Curr Drug Metab 11: 182-196, 2010.
17. Oh YK and Park TG: siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev 6: 850-862, 2009.
18. Castanotto D and Rossi JJ: The promises and pitfalls of RNA-interference-based therapeutics. Nature 457: 426-433, 2009.
19. Urban-Klein B, Werth S, Abuharbeid S, et al: RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 12: 461-466, 2005.
20. Boussif O, Lezoualc'h F, Zanta MA, et al: A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 92: 7297-7301, 1995.
21. Franklin WA, Veve R, Hirsch FR, et al: Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 29: 3-14, 2002.
22. Tuschl T, Zamore PD, Lehmann R, et al: Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev 13: 3191-3197, 1999.
23. Schiffelers RM, Ansari A, Xu J, et al: Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 32: e149, 2004.
24. Weihua Z, Tsan R, Huang WC, et al: Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 13: 385-393, 2008.
25. Tan Y, Sun X, Xu M, et al: Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice. Clin Cancer Res 5: 2157-2163, 1999.
26. Bruyere C, Lonez C, Duray A, et al: Considering temozolomide as a novel potential treatment for esophageal cancer. Cancer 117: 2004-2016, 2010.
27. Yang H, Che O, Chen S, et al: Silence of VEGFR2 expression mediated by PEI/siRNA complexes. Yao Xue Xue Bao 45: 576-581, 2010 (In Chinese).
28. Dvorak HF: Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315: 1650-1659, 1986.
29. Risau W: Mechanisms of angiogenesis. Nature 386: 671-674, 1997.
30. Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996.
31. Murukesh N, Dive C and Jayson GC: Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 102: 8-18, 2010.
32. Nyberg P, Xie L and Kalluri R: Endogenous inhibitors of angiogenesis. Cancer Res 65: 3967-3979, 2005.
33. Ohsaki Y, Tanno S, Fujita Y, et al: Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 7: 603-607, 2000.
34. Wu W, Onn A, Isobe T, et al: Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther 6: 471-483, 2007.
35. Slaton JW, Perrotte P, Inoue K, et al: Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 5: 2726-2734, 1999.
36. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003.
37. Hanahan D, Bergers G and Bergsland E: Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105: 1045-1047, 2000.
38. Jain RK: Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 19: 7-16, 2005.
39. Higgins KJ, Abdelrahim M, Liu S, et al: Regulation of vascular endothelial growth factor receptor-2 expression in pancreatic cancer cells by Sp proteins. Biochem Biophys Res Commun 345: 292-301, 2006.
40. Hobel S, Koburger I, John M, et al: Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab. J Gene Med 12: 287-300, 2010.